Insights

Liquid Biopsy Innovation Genomic Health Inc. has recently launched a liquid biopsy test, Oncotype SEQ Liquid Select, which detects genomic alterations in late-stage cancers. This innovative test presents a sales opportunity for targeting healthcare providers seeking advanced diagnostic solutions for cancer patients.

Expansion of Test Portfolio With an expanding test portfolio that now includes tissue-based tests like the Oncotype SEQ Liquid Select, Genomic Health is opening new avenues for sales engagements. Organizations involved in precision medicine and personalized treatment can benefit by offering these cutting-edge tests to their patient population.

Strategic Partnership The partnership between Genomic Health Inc. and MDxHealth for the acquisition of the Oncotype DX Genomic Prostate Score test not only strengthens their test offering but also provides a collaborative sales opportunity. Sales teams can now explore cross-selling opportunities to leverage the combined expertise and resources of both companies.

Strong Market Position Having tested over 750,000 patients in more than 90 countries with their Oncotype DX tests, Genomic Health Inc. enjoys a strong global presence. Sales development representatives can capitalize on this market leadership to increase sales by targeting healthcare facilities looking to adopt proven genomic-based diagnostic solutions.

Financial Backing and Investments With investments from companies like Exact Sciences and Mutual Of America Capital Limited Liability, Genomic Health Inc. showcases financial stability and growth potential. Sales professionals can leverage the company's financial backing to instill confidence in potential clients and drive sales conversations with healthcare institutions looking for reliable partners.

Genomic Health Tech Stack

Genomic Health uses 8 technology products and services including SAS, Python, New Relic, and more. Explore Genomic Health's tech stack below.

  • SAS
    Business Intelligence
  • Python
    Programming Languages
  • New Relic
    Real User Monitoring
  • Google Tag Manager
    Tag Management
  • Microsoft ASP.NET
    Web Frameworks
  • Nginx
    Web Servers
  • Google Plus
    Widgets
  • Linkedin
    Widgets

Media & News

Genomic Health's Email Address Formats

Genomic Health uses at least 1 format(s):
Genomic Health Email FormatsExamplePercentage
flast@genomichealth.comJDoe@genomichealth.com
82%
first.last@genomichealth.comJohn.Doe@genomichealth.com
16%
fmiddlelast@genomichealth.comJMichaelDoe@genomichealth.com
1%
last@genomichealth.comDoe@genomichealth.com
1%

Frequently Asked Questions

Where is Genomic Health's headquarters located?

Minus sign iconPlus sign icon
Genomic Health's main headquarters is located at 301 Penobscot Dr. Redwood City, CA 94063 US. The company has employees across 6 continents, including North AmericaEuropeAsia.

What is Genomic Health's phone number?

Minus sign iconPlus sign icon
You can contact Genomic Health's main corporate office by phone at +1-650-556-9300. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Genomic Health's stock symbol?

Minus sign iconPlus sign icon
Genomic Health is a publicly traded company; the company's stock symbol is GHDX.

What is Genomic Health's official website and social media links?

Minus sign iconPlus sign icon
Genomic Health's official website is genomichealth.com and has social profiles on LinkedIn.

How much revenue does Genomic Health generate?

Minus sign iconPlus sign icon
As of May 2024, Genomic Health's annual revenue reached $750M.

What is Genomic Health's SIC code NAICS code?

Minus sign iconPlus sign icon
Genomic Health's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Genomic Health have currently?

Minus sign iconPlus sign icon
As of May 2024, Genomic Health has approximately 323 employees across 6 continents, including North AmericaEuropeAsia. Key team members include CSO: J. B.Chief Compliance Officer: J. S.Chief Scientific Officer: S. S.. Explore Genomic Health's employee directory with LeadIQ.

What industry does Genomic Health belong to?

Minus sign iconPlus sign icon
Genomic Health operates in the Biotechnology Research industry.

What technology does Genomic Health use?

Minus sign iconPlus sign icon
Genomic Health's tech stack includes SASPythonNew RelicGoogle Tag ManagerMicrosoft ASP.NETNginxGoogle PlusLinkedin.

What is Genomic Health's email format?

Minus sign iconPlus sign icon
Genomic Health's email format typically follows the pattern of . Find more Genomic Health email formats with LeadIQ.

When was Genomic Health founded?

Minus sign iconPlus sign icon
Genomic Health was founded in 2000.
Genomic Health

Genomic Health

Biotechnology ResearchCalifornia, United States501-1000 Employees

About Genomic Health 
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 750,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ® Liquid Select™ test. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth,  Facebook, YouTube and LinkedIn.

About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX Breast Recurrence Score®, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the Oncotype DX Breast DCIS Score™ predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. In prostate cancer, the Oncotype DX Genomic Prostate Score™ predicts disease aggressiveness and further clarifies the current and future risk of the cancer prior to treatment intervention. With more than 750,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeIQ.com, www.MyBreastCancerTreatment.org or www.MyProstateCancerTreatment.org.

Section iconCompany Overview

Headquarters
301 Penobscot Dr. Redwood City, CA 94063 US
Phone number
+1-650-556-9300
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
GHDX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2000
Employees
501-1000

Section iconFunding & Financials

  • $100M$1B

    Genomic Health's revenue is in the range of $100M$1B

Section iconFunding & Financials

  • $100M$1B

    Genomic Health's revenue is in the range of $100M$1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.